IGF2 and hepatocellular carcinoma: In an experimental model of HCC, CTNNB1, IGF1R, FGF19, CCND1 and IGF2 have been evaluated in the oncogenic addiction loop, but this study has yet to enter the advanced clinical developmental phase [19].